First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...
Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds ...
Q3 2025 Earnings Call Transcript November 13, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.04, ...
Vaxart Inc (VXRT) announces a major partnership with Dynavax and reports significant revenue growth, while navigating market ...
Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, ...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...
Outbreaks of norovirus, an extremely contagious stomach bug, can spread quickly. “‘Tis the season for germs,” said Dr.
One of the common signs they may be better off at home is a high temperature and with other illnesses, such as diarrhoea and ...
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...
Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine candidate, positioning the biotech to see phase 2b data before placing a bigger bet on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback